BioBio schreef op 24 augustus 2020 09:31:
[...]
dat klopt, had niemand verwacht buiten de FDA .
dan laten we ons maar positief verassen doe de EU.
en zoals eerder gezegd bijwerking van Rinvoq zijn ook niet mis (ten minste wat in de bijsluiter staat):
Rinvoq was effective at controlling moderate to severe rheumatoid arthritis in patients whose disease had not improved enough with other disease-modifying anti-rheumatic medicines. Studies found that it reduced disease activity when used alone or combined with other medicines. Patients treated with Rinvoq may have side effects that include infection, neutropenia (low count of a type of white blood cell), and blood tests that suggest liver or muscle damage and raised blood lipids. However, these side effects are considered manageable.
The European Medicines Agency therefore decided that Rinvoq’s benefits are greater than its risks and that it can be authorised for use in the EU.